title: Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases.
abstract: BACKGROUND
  Since 1997, immunological modulators have been used for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in the Multiple Sclerosis Attendance and Treatment Center (CATEM) with significant alterations in this disease natural history.
  
  
  OBJECTIVE
  To add data on the experience of CATEM for the treatment of RRMS patients that had immunomodulators.
  
  
  METHODS
  RRMS patients that received continuously immunomodulator drugs were evaluated on adherence, migration, withdrawal and progression rates. The patients were divided in three groups by the period of immunomodulators intake.
  
  
  RESULTS
  There were registered in Group 1 withdrawal in 98 patients (25%) and adherence in 292 cases (74%); Group 2 interruption of therapy in 140 patients, 92 (31%) due to progression for PSMS, 14 (5%) for pregnancy, withdrawal in 34 (11%), adherence in 88%; Group 3 progression in 41 (26%), pregnancy in 3 (2%) withdrawal in 42 (27%) and adherence in 72%. The migration rate was about one third (31.57%) and the principal cause was therapeutic failure; the mean migrating time was 0.5-2.5 years in group 3.
  
  
  CONCLUSIONS
  Immunomodulatory treatment for RRMS patients may have significant levels of failure and side effects; the adherence was compatible with the international literature.
authors.affiliation: Neurology Department, Multiple Sclerosis Attendance and Treatment Center, College of Medical Science, Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil. sjordy@einstein.br
authors.forename: Sergio Semeraro
authors.initials: SS
authors.lastname: Jordy
authors.forename: Charles Peter
authors.initials: CP
authors.lastname: Tilbery
authors.forename: Mirella Martins
authors.initials: MM
authors.lastname: Fazzito
mesh_terms: D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010349:Patient Compliance / Q000706:statistics & numerical data; D010352:Patient Dropouts / Q000706:statistics & numerical data; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D016899:Interferon-beta